Zhonghua Yi Xue Za Zhi. 2023 Sep 5;103(33):2552-2570. doi: 10.3760/cma.j.cn112137-20230604-00933.
The standardization of surgical treatment has become indispensable in the overall outcome of esophageal cancer care in China, but there is a notable deficiency of clinical guidelines regarding esophageal surgery. The Chinese National Cancer Center organized esophageal surgery experts from the Chinese Association of Thoracic Surgeons (CATS), Chinese Society for Thoracic and Cardiovascular Surgery (CSTCVS), and Chinese Society for Disease of the Esophagus (CSDE) to develop and establish the Chinese Guidelines on Perioperative Management of Resectable Esophageal Cancer (2023 edition). This guideline comprehensively covers all aspects of surgical treatment for esophageal cancer, including conceptual clarification, preoperative diagnosis, clinical staging, indications for surgery, multidisciplinary comprehensive treatment, surgical treatment modalities, and perioperative management. A total of 39 critical clinical questions are categorized into six domains above. This guideline follows the globally accepted approach for developing recommendations and takes into account the most recent research evidence as well as China's unique national circumstances. Its main aim is to serve as a comprehensive resource for standardizing the diagnosis and surgical treatment of esophageal cancer in China, with the ultimate goal of substantially improving the overall outcomes.
手术治疗的规范化在中国食管癌治疗的整体结果中已变得不可或缺，但关于食管手术的临床指南存在显著不足。中国国家癌症中心组织了来自中国胸外科医师协会（CATS）、中国胸心血管外科学会（CSTCVS）和中国食管疾病学会（CSDE）的食管外科专家制定并建立了《中国可切除食管癌围手术期管理指南（2023年版）》。本指南全面涵盖了食管癌手术治疗的各个方面，包括概念澄清、术前诊断、临床分期、手术指征、多学科综合治疗、手术治疗方式以及围手术期管理。总共39个关键临床问题被归类到上述六个领域。本指南遵循全球公认的制定推荐意见的方法，并考虑了最新的研究证据以及中国独特的国情。其主要目的是作为规范中国食管癌诊断和手术治疗的综合资源，最终目标是大幅改善整体治疗效果。
